APOA1 and Impaired glucose tolerance: The observations that aleglitazar improved glucose and lipid regulation in a non-human primate model of the metabolic syndrome and impaired glucose tolerance (prediabetes), are largely consistent with previously published studies of aleglitazar in other animal models including Zucker Diabetic Fatty (ZDF) rats and human ApoAI-transgenic mice [22].